9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

This study is comparing two treatments for people with locally advanced cervical cancer that cannot be removed by surgery: a combination of 9MW2821 (a targeted antibody-drug) plus toripalimab (an immunotherapy), versus 9MW2821 alone. **You may be eligible if...** - You are 18–70 years old - You have locally advanced cervical cancer that cannot be surgically removed - You have not received prior systemic chemotherapy or immunotherapy for this cancer - Your cancer is confirmed by biopsy - You are in reasonably good physical health (ECOG score 0–1) - Your organ function (kidneys, liver, bone marrow) is within normal ranges **You may NOT be eligible if...** - Your cancer has spread to distant organs (stage IVB) - You have already received chemotherapy or radiation for this cancer - You have active autoimmune disease - You are pregnant or breastfeeding - You have serious heart, lung, or liver conditions Talk to your doctor to see if this trial is right for you.